These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 38860446)

  • 1. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
    Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.
    Zhou H; Zheng H; Peng Y; Su Y; Yu X; Wang W; Li S; Ding Y; Jiao S; Wang Y; Zhu X; Luo L; Dong Z; Liu L; Zhang F; Wu Q; Li J; Zhu F
    Front Immunol; 2024; 15():1407826. PubMed ID: 38903523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Su YW; Qiu YZ; Wang YH; Xu Y; Huang CC; Zhang Q; Su C; Ma JH; Liu W; Liu Y; Zhao MS; Yang HY; Li CL; Lu X
    Vaccine; 2024 Apr; 42(9):2438-2447. PubMed ID: 38461050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
    Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE
    Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
    Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
    J Infect Dis; 2024 Jul; 230(1):e4-e16. PubMed ID: 39052718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
    Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
    Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.
    Huang J; Qiu Y; Luo L; Wu J; Hu D; Zhong X; Lin J; Guo L; Yang H; Li C; Wang X
    J Med Virol; 2024 Mar; 96(3):e29542. PubMed ID: 38506170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
    Chen GL; Qiu YZ; Wu KQ; Wu Y; Wang YH; Zou YY; Peng CG; Zhao J; Su C; Ma JH; Ni SN; Wang X; Jin TH; Jiang Q; Guo T; Xu Y; Huang CC; Zhang Q; Liu KL; Ji L; Yang HY; Li CL; Su YW; Lu X; Li LJ
    Hum Vaccin Immunother; 2023 Dec; 19(3):2285089. PubMed ID: 38111106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial.
    Hannawi S; Wu XH; Villalobos RE; Burhan E; Lallaine Borra MD; Gupta RK; Aquitania GP; Ang BWC; Mae A Zabat G; Roa CC; Zoleta-De Jesus L; Yu DD; Wang M; Wu Y; Song WJ; Ying B; Qin CF
    Med; 2024 Oct; 5(10):1282-1292.e3. PubMed ID: 39025066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Dinh Thiem V; Van Anh PT; Van Men C; Hung DT; Pollard AJ; Kamitani A; Tada Y; Fukuyama H; Iwasaki Y; Ariyasu M; Sonoyama T
    Vaccine; 2024 Jun; 42(17):3699-3709. PubMed ID: 38734495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Li J; Hou L; Guo X; Jin P; Wu S; Zhu J; Pan H; Wang X; Song Z; Wan J; Cui L; Li J; Chen Y; Wang X; Jin L; Liu J; Shi F; Xu X; Zhu T; Chen W; Zhu F
    Nat Med; 2022 Feb; 28(2):401-409. PubMed ID: 35087233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Lawpoolsri S; Nanthapisal S; Jongkaewwattana A; Duangdee C; Kamolratanakul S; Luvira V; Thanthamnu N; Chantratita N; Thitithanyanont A; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2024 Jul; 42(19):3999-4010. PubMed ID: 38744598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
    Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.